California Voters to Decide Future of Stem Cell Funding Agency

If approved, Proposition 14 would authorize the state to sell $5.5 billion in bonds to extend the life of CIRM, which funds stem cell research. The ballot measure has its critics.

Written byKatarina Zimmer
| 6 min read
a pipette dropping clear liquid into a well plate

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

ABOVE: © ISTOCK.COM, CIPHOTOS

Over the course of its 16-year existence, the California Institute for Regenerative Medicine in Oakland has helped transform its state into an innovation hub of stem cell science. But CIRM announced last year that its first $3 billion of funding has dried up, and now it’s up to voters to decide on November 3 whether to give the agency a second life.

The Stem Cell Research Institute Bond Initiative, Proposition 14, would issue $5.5 billion in general obligation bonds for the agency to continue funding stem cell studies, training scientists, and building new research facilities, with the aim of developing and testing treatments for a range of diseases.

The measure isn’t facing significant organized opposition, but it has drawn criticism from newspaper editorial boards and others for what they see as conflicts of interest between CIRM board members and institutions applying for funds. Critics also question ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies